Know Cancer

or
forgot password

Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma: a Multicentric Study


N/A
18 Years
N/A
Open (Enrolling)
Both
Multiple Myeloma

Thank you

Trial Information

Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma: a Multicentric Study


Inclusion Criteria:



- Inscription to medical assurance

- Patients who gave their written consent

- Patients with newly diagnosed Multiple Myeloma required chemotherapy

Exclusion Criteria:

- Patients with renal failure who need to undergo hemodialysis

- Patients with indication for curative anticoagulant therapy

- Patient with 3 month follow-up not possible

- Patient with life expectancy < 6 month

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

change from baseline in Thrombin generation measure

Outcome Description:

change from baseline in Thrombin generation measure

Outcome Time Frame:

day 21

Safety Issue:

No

Principal Investigator

Bernard TARDY, MD-PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

CHU de Saint-Etienne - CIC-EC (CIE3)

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

1108178

NCT ID:

NCT01508416

Start Date:

January 2012

Completion Date:

June 2013

Related Keywords:

  • Multiple Myeloma
  • Multiple Myeloma
  • Newly diagnosed
  • Thrombin generation
  • TFPI
  • Tissue Factor pathway inhibitor
  • Protein S
  • Thrombosis
  • Chemotherapy
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location